Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q1998021> ?p ?o }
Showing triples 1 to 31 of
31
with 100 triples per page.
- Q1998021 subject Q7211373.
- Q1998021 abstract "Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2-positive breast cancer, in combination with trastuzumab and docetaxel. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth. Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer on June 8, 2012. Pertuzumab was developed at Genentech and is now owned by Roche which acquired Genentech in 2009.".
- Q1998021 atcPrefix "L01".
- Q1998021 atcSuffix "XC13".
- Q1998021 casNumber "380610-27-5".
- Q1998021 fdaUniiCode "K16AIQ8CTM".
- Q1998021 thumbnail Pertuzumab-HER2_complex_1S78.png?width=300.
- Q1998021 wikiPageExternalLink www.perjeta.com.
- Q1998021 wikiPageWikiLink Q12078.
- Q1998021 wikiPageWikiLink Q128581.
- Q1998021 wikiPageWikiLink Q14877486.
- Q1998021 wikiPageWikiLink Q2112244.
- Q1998021 wikiPageWikiLink Q212646.
- Q1998021 wikiPageWikiLink Q412616.
- Q1998021 wikiPageWikiLink Q420436.
- Q1998021 wikiPageWikiLink Q422248.
- Q1998021 wikiPageWikiLink Q6589727.
- Q1998021 wikiPageWikiLink Q7211373.
- Q1998021 wikiPageWikiLink Q899140.
- Q1998021 atcPrefix "L01".
- Q1998021 atcSuffix "XC13".
- Q1998021 casNumber "380610".
- Q1998021 unii "K16AIQ8CTM".
- Q1998021 type ChemicalSubstance.
- Q1998021 type Drug.
- Q1998021 type ChemicalObject.
- Q1998021 type Thing.
- Q1998021 type Q8386.
- Q1998021 comment "Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2-positive breast cancer, in combination with trastuzumab and docetaxel. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.".
- Q1998021 label "Pertuzumab".
- Q1998021 depiction Pertuzumab-HER2_complex_1S78.png.